| Patient-derived tumour xenografts as models for oncology drug development JJ Tentler, AC Tan, CD Weekes, A Jimeno, S Leong, TM Pitts, JJ Arcaroli, ... Nature reviews Clinical oncology 9 (6), 338-350, 2012 | 1366 | 2012 |
| Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology AB Benson, AP Venook, MM Al-Hawary, MA Arain, YJ Chen, KK Ciombor, ... Journal of the National Comprehensive Cancer Network 19 (3), 329-359, 2021 | 935 | 2021 |
| NCCN guidelines insights: colon cancer, version 2.2018 AB Benson, AP Venook, MM Al-Hawary, L Cederquist, YJ Chen, ... Journal of the National Comprehensive Cancer Network 16 (4), 359-369, 2018 | 871 | 2018 |
| Rectal cancer, version 2.2018, NCCN clinical practice guidelines in oncology AB Benson, AP Venook, MM Al-Hawary, L Cederquist, YJ Chen, ... Journal of the National Comprehensive Cancer Network 16 (7), 874-901, 2018 | 865 | 2018 |
| Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology AB Benson, AP Venook, L Cederquist, E Chan, YJ Chen, HS Cooper, ... Journal of the National Comprehensive Cancer Network 15 (3), 370-398, 2017 | 759 | 2017 |
| Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial GS Falchook, KD Lewis, JR Infante, MS Gordon, NJ Vogelzang, ... The lancet oncology 13 (8), 782-789, 2012 | 592 | 2012 |
| Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial JR Infante, LA Fecher, GS Falchook, S Nallapareddy, MS Gordon, ... The lancet oncology 13 (8), 773-781, 2012 | 575 | 2012 |
| Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600–mutant colorectal cancer RB Corcoran, CE Atreya, GS Falchook, EL Kwak, DP Ryan, JC Bendell, ... Journal of clinical oncology 33 (34), 4023, 2015 | 533 | 2015 |
| An in vivo platform for translational drug development in pancreatic cancer B Rubio-Viqueira, A Jimeno, G Cusatis, X Zhang, C Iacobuzio-Donahue, ... Clinical cancer research 12 (15), 4652-4661, 2006 | 487 | 2006 |
| NCCN guidelines insights: rectal cancer, version 6.2020: featured updates to the NCCN guidelines AB Benson, AP Venook, MM Al-Hawary, MA Arain, YJ Chen, KK Ciombor, ... Journal of the National Comprehensive Cancer Network 18 (7), 806-815, 2020 | 397 | 2020 |
| Efficacy and safety of anti-trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer A Bardia, IA Mayer, JR Diamond, RL Moroose, SJ Isakoff, AN Starodub, ... Journal of Clinical Oncology 35 (19), 2141, 2017 | 374 | 2017 |
| Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors AW Tolcher, WA Messersmith, SM Mikulski, KP Papadopoulos, EL Kwak, ... Journal of clinical oncology 30 (19), 2348, 2012 | 271 | 2012 |
| KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection A Jimeno, WA Messersmith, FR Hirsch, WA Franklin, SG Eckhardt J Clin oncol 27 (7), 1130-1136, 2009 | 265 | 2009 |
| The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma IR Kamel, DA Bluemke, J Eng, E Liapi, W Messersmith, DK Reyes, ... Journal of Vascular and Interventional Radiology 17 (3), 505-512, 2006 | 253 | 2006 |
| Colon cancer, version 3.2014 AB Benson, AP Venook, T Bekaii-Saab, E Chan, YJ Chen, HS Cooper, ... Journal of the National Comprehensive Cancer Network 12 (7), 1028-1059, 2014 | 242 | 2014 |
| Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology AB Benson, AP Venook, MM Al-Hawary, N Azad, YJ Chen, KK Ciombor, ... Journal of the National Comprehensive Cancer Network 20 (10), 1139-1167, 2022 | 233 | 2022 |
| Rectal cancer, version 2.2015 AB Benson, AP Venook, T Bekaii-Saab, E Chan, YJ Chen, HS Cooper, ... Journal of the National Comprehensive Cancer Network 13 (6), 719-728, 2015 | 231 | 2015 |
| A Phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014 WA Messersmith, GI Shapiro, JM Cleary, A Jimeno, A Dasari, B Huang, ... Clinical Cancer Research 21 (1), 60-67, 2015 | 220 | 2015 |
| Pharmacogenetic pathway analysis of docetaxel elimination SD Baker, J Verweij, GA Cusatis, RH Van Schaik, S Marsh, SJ Orwick, ... Clinical Pharmacology & Therapeutics 85 (2), 155-163, 2009 | 195 | 2009 |
| A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors DS Hong, DW Bowles, GS Falchook, WA Messersmith, GC George, ... Clinical Cancer Research 18 (15), 4173-4182, 2012 | 189 | 2012 |
Antonio Jimeno M.D., Ph.D.ProfessorVerified email at ucdenver.edu
